| 【Company Research】Baozun (BZUN US) - 2Q loss reduction trend better than expectation |
| 【Company Research】BYDE (285 HK) - Positive on multiple growth drivers ahead despite near-term drags from Jabil integration |
| 【Company Research】AK Medical (1789 HK) - Resilient performance in 1H24, expecting recovery in 2H24 |
| 【Company Research】Salesforce (CRM US) - cRPO growth reaccelerates; eyes on new AI product launch |
| 【Company Research】Innovent Biologics (1801 HK) - 2025 EBITDA breakeven goal unchanged |
| 【Company Research】SANY International (631 HK) - Scale-down of solar power expansion plan a positive move |
| 【Company Research】Tigermed (300347 CH) - Order growth in 1H24 signals reduced uncertainties in demand recovery |
| 【Company Research】Tongda (698 HK) - Non-metal casing upgrade and Smart-tech to drive earnings recovery in FY25E |
| 【Company Research】Great Wall Motor (2333 HK) - Strong earnings to continue with a new H6 needed |
| 【Company Research】BYD (1211 HK) - Solid sales, earnings outlook despite mixed 2Q |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2024 CMB International Capital Corporation Limited. All rights reserved.
